What Researchers Did
Researchers evaluated the efficacy of 12 different antihypoxants or hyperbaric oxygenation as part of intensive care in 385 acute myocardial infarction patients compared to 235 patients receiving traditional treatment.
What They Found
Among 620 patients with acute myocardial infarction, 385 received one of 12 antihypoxants or hyperbaric oxygenation, while the remaining patients received traditional treatment. Amtizol, lithium hydroxybutyrate, piracetam, and ubiquinone showed the highest protective effects, with cytochrome C, riboxine, mildronate, and olifen being somewhat less active. In contrast, solcoseryl, bemitil, trimethasidine, and aspisol were the least effective, and hyperbaric oxygenation offered virtually no protective benefit.
What This Means for Canadian Patients
Canadian patients with acute myocardial infarction might potentially benefit from specific antihypoxants, though these findings require contemporary research and clinical trials. Currently, standard Canadian treatment protocols for myocardial infarction do not typically include these specific antihypoxants, so these findings are not immediately applicable without further investigation.
Canadian Relevance
This study has no direct Canadian connection as it was conducted outside of Canada and does not involve Canadian researchers or patient populations.
Study Limitations
Limitations include the study's age (1998), potentially small group sizes for individual drug comparisons, and the use of a proposed, non-standard assessment parameter.